Summing the risk of NSAID therapy

Summing the risk of NSAID therapy

The importance of individualised risk assessment and its role on a single NSAID-related safety outcome is exemplified in the study by Frances Chan and colleagues in today's Lancet.3 They report that the twice-daily addition of a proton-pump inhibitor to twice daily celecoxib lowered the 13-mont...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2007-05, Vol.369 (9573), p.1580-1581
Hauptverfasser: Scheiman, James M, Fendrick, A Mark
Format: Artikel
Sprache:eng
Schlagworte:
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Aspirin
Cardiovascular Diseases - prevention & control
Combined treatment
Cyclooxygenase Inhibitors - adverse effects
Cyclooxygenase Inhibitors - therapeutic use
Data collection
Gastrointestinal Diseases - chemically induced
Humans
Internal Medicine
Nonsteroidal anti-inflammatory drugs
Risk Assessment
Side effects
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The importance of individualised risk assessment and its role on a single NSAID-related safety outcome is exemplified in the study by Frances Chan and colleagues in today's Lancet.3 They report that the twice-daily addition of a proton-pump inhibitor to twice daily celecoxib lowered the 13-month recurrence of ulcer bleeding to 0% in the combined treatment group compared with 8.9% with celecoxib alone (95% CI for the difference, 4.1-13.7).
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(07)60722-3